Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy
about
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceEligibility of persons who inject drugs for treatment of hepatitis C virus infection.Psychiatric treatment considerations with direct acting antivirals in hepatitis CEffect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapyNew developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Reduced pupil diameter in volunteers on stable buprenorphine maintenance therapy with telaprevir: a drug-drug interaction involving p-glycoprotein at the blood-brain barrier?Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy.Hepatitis C virus prevention and care for drug injectors: the French approach
P2860
Q27692040-A7C55093-B3FB-4102-A155-29B4F0FC9CDBQ30429470-5358EF09-8CF3-40AD-AA51-9BE6F0031484Q34721628-40E47E9F-55F7-4C62-A0D1-921689678D93Q34922818-70E784A7-918E-4EA8-B144-783F245ACFCEQ34952233-F7B04CEA-0340-417D-8756-91D8ECB3BF7CQ38095820-D1B96985-369A-4D8E-94E4-5A7F11A442C2Q38210969-54C4B0AF-C75C-414E-8A28-1746733A5F26Q38435908-58EEBD00-F747-4300-A7AB-5C999F873F6CQ38824198-955E750E-B534-4E51-8357-E7ADD70D6621Q40785885-8DBDC120-5505-4193-8AD9-A029BD51ED40Q41047662-727D1E8F-1A3B-4E57-B596-182F378F80B4Q42280296-E0A2D42E-A8AD-4939-842C-E59E72361C64Q42383078-10190E40-7BD2-4904-A464-281F2F558576Q44349587-3F7F4412-C7C2-4185-A68B-0752F234468EQ57144432-1AB8528C-18E0-458D-9538-406B28F5B67C
P2860
Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effect of telaprevir on the ph ...... e/naloxone maintenance therapy
@ast
Effect of telaprevir on the ph ...... e/naloxone maintenance therapy
@en
type
label
Effect of telaprevir on the ph ...... e/naloxone maintenance therapy
@ast
Effect of telaprevir on the ph ...... e/naloxone maintenance therapy
@en
prefLabel
Effect of telaprevir on the ph ...... e/naloxone maintenance therapy
@ast
Effect of telaprevir on the ph ...... e/naloxone maintenance therapy
@en
P2093
P2860
P356
P1476
Effect of telaprevir on the ph ...... e/naloxone maintenance therapy
@en
P2093
Frances Smith
Jose Trevejo
Rolf P G van Heeswijk
Varun Garg
P2860
P304
P356
10.1128/AAC.00077-12
P407
P577
2012-05-07T00:00:00Z